Wave Life Sciences Ltd. — Q1 2019 Form 10-Q
Business context and period: Clinical-stage genetic medicines company developing stereopure oligonucleotide therapies using its PRISM platform. This unaudited report covers the three months ended March 31, 2019; comparisons are to Q1 2018 unless otherwise stated. The company had no product sales; revenue came from Pfizer and Takeda collaborations.
Key financial metrics
| Metric | Q1 2019 | Q1 2018 / prior balance date |
|---|---|---|
| Revenue | $3.0 million | $1.4 million |
| Research and development expense | $40.1 million | $29.2 million |
| General and administrative expense | $10.9 million | $8.0 million |
| Operating loss | $48.0 million | $35.8 million |
| Net loss | $44.2 million; $1.36 per share | $35.2 million; $1.26 per share |
| Operating cash used | $50.4 million | $32.4 million |
| Cash and cash equivalents | $287.6 million | $174.8 million at Dec. 31, 2018 |
| Current assets / current liabilities | $315.0 million / $131.9 million | $202.3 million / $130.0 million at Dec. 31, 2018 |
| Total liabilities | $225.9 million | $214.7 million at Dec. 31, 2018 |
Gross margin is not presented. No conventional debt balance is identified in the supplied filing text; operating lease liabilities totaled $34.7 million at March 31, 2019. The company reported $3.6 million of restricted cash and an accumulated deficit of $383.9 million.
Changes versus prior period
- Revenue rose $1.6 million, primarily reflecting Takeda collaboration revenue, which was absent in Q1 2018.
- Operating expenses increased $13.8 million. R&D rose $10.9 million, principally from higher suvodirsen/DMD trial spending and broader platform and discovery costs; G&A increased $2.9 million, mainly from headcount-related compensation.
- Net loss widened by $9.0 million despite other income increasing to $3.8 million from $0.7 million. The increase included an estimated UK R&D tax credit and higher dividend income.
- Operating cash use increased $18.0 million. The January–February follow-on offering generated approximately $162.1 million net proceeds, lifting cash and increasing ordinary shares outstanding to 34.3 million from 29.5 million at year-end.
- Adoption of ASC 842 on January 1, 2019 added operating lease assets and liabilities; management said the adoption did not materially affect results or cash flows.
Outlook, commentary, and risks
- Management said existing cash and cash equivalents were expected to fund operations for at least the next 12 months, while cautioning that assumptions could prove incorrect. The company expects expenses and operating losses to increase and may need additional financing.
- Management expected to initiate the suvodirsen global Phase 2/3 DYSTANCE 51 trial in July 2019. It remained on track to deliver interim open-label-extension data in the second half of 2019 and, subject to positive data, expected to submit for U.S. accelerated approval in the second half of 2020.
- Topline data from the PRECISION-HD trials were expected by year-end 2019. U.S. multiple-dose portions could not proceed until additional preclinical work was completed and reviewed by FDA; escalation to the highest proposed U.S. single doses also required FDA review of monitoring plans.
- WVE-N531 topline data were anticipated in the second half of 2020, subject to clinical-trial applications and authorization. The company expected to announce its first ophthalmology candidate in the second half of 2019; initiation of WVE-C092 clinical development was projected for the second half of 2020, subject to regulatory submissions and approval.
- In April 2019, the company reported Phase 1 single-dose suvodirsen results: generally well tolerated, with no serious adverse events, deaths, or adverse-event discontinuations reported. Common events included infusion-associated symptoms; filing disclosure does not establish efficacy.
- Principal risks include clinical and regulatory uncertainty, the need for substantial future capital, competition, intellectual-property protection, and dependence on collaboration partners. The filing reported no material change to previously disclosed risk factors and no material legal proceedings.
Investor verification priorities
- Track cash burn against management’s stated 12-month-plus runway, including subsequent financing, collaboration receipts, and changes in trial spending.
- Verify suvodirsen trial timing and whether interim dystrophin data support the proposed accelerated-approval path; distinguish safety findings from evidence of clinical benefit.
- Monitor FDA requirements and timing for the U.S. Huntington’s disease multiple-dose studies and the planned DMD Phase 2/3 trial.
- Review the terms, remaining obligations, revenue recognition, and potential milestone or option payments under the Pfizer and Takeda collaborations; these payments are not all guaranteed.
- Assess dilution from equity issuance and equity compensation, and confirm the nature and duration of lease liabilities and other commitments.